Genetic Polymorphisms Contribute to the Individual Variations of Imatinib Mesylate Plasma Levels and Adverse Reactions in Chinese GIST Patients

Genetic Polymorphisms Contribute to the Individual Variations of Imatinib Mesylate Plasma Levels and Adverse Reactions in Chinese GIST Patients

Imatinib mesylate (IM) has dramatically improved the outcomes of gastrointestinal stromal tumor (GIST) patients. However, the clinical responses of IM may considerably vary among single individuals. This study aimed to investigate the influences of genetic polymorphisms of drug-metabolizing enzyme (...

Full description

Bibliographic Details
Main Authors: Jing Liu, Zhiyu Chen, Hanmei Chen, Yingyong Hou, Weiqi Lu, Junyi He, Hanxing Tong, Yuhong Zhou, Weimin Cai
Format: Article
Language:English
Published: MDPI AG 2017-03-01
Series:International Journal of Molecular Sciences
Subjects:
imatinib mesylate
gastrointestinal stromal tumor
genetic polymorphisms
plasma levels
adverse reactions
Chinese
Online Access:http://www.mdpi.com/1422-0067/18/3/603

Similar Items

Similar Items